Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Schrum Private Wealth Management LLC

Schrum Private Wealth Management LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 54.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,234 shares of the medical instruments supplier’s stock after selling 1,466 shares during the period. Schrum Private Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Sierra Ocean LLC acquired a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $33,000. Tompkins Financial Corp boosted its position in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company during the third quarter worth $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Barclays increased their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $278.29.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 in the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0 %

BDX opened at $224.17 on Thursday. The company has a 50-day simple moving average of $233.02 and a 200 day simple moving average of $232.83. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The stock has a market capitalization of $64.37 billion, a price-to-earnings ratio of 37.24, a P/E/G ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company announced that its board has authorized a share buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.